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ABSTRACT 
 
Background:  The presence of Extended-Spectrum β-lactamase 
(ESBL) producing organisms significantly affects the course and 
outcome of an infection and poses a challenge to infection 
management worldwide. Hence, the knowledge about their 
prevalence is important to guide towards appropriate antibiotic 
treatment. 
Aims & Objective: The purpose of this study is to determine the 
prevalence and susceptibility of ESBL in Escherichia Coli isolated 
from different clinical samples. 
Methods: A total of 100 isolates of E. Coli were collected over a 
period of six months. Antimicrobial susceptibility testing was 
determined by commonly used antibiotics using Kirby-Bauer’s 
disc diffusion method. ESBL detection was done by the screening 
method and then confirmed by the phenotypic confirmatory test 
with combination disc and the minimum inhibitory concentration 
(MIC) reduction test as recommended by the (CLSI). 
Results: Out of 100 E. coli isolates, 69 were positive by screening 
test and 58 were potential ESBL producers by combination disc 
and MIC reduction test. Multidrug resistance was significantly (p 
< 0.01) higher in ESBL positive isolates. 
Conclusion: Knowledge of the prevalence of ESBL and resistance 
pattern of bacterial isolates in a geographical area will help the 
clinicians to formulate the guidelines for antibiotic therapy.  
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INTRODUCTION 
Over last 20 years, β-lactam antibiotics 
(penicillins, cephalosporins, carbapenemsetc.) 
are most commonly used drugs. Introduction of 
third generation cephalosporinsduring early 
1980s, was major breakthrough in fight against 
β-lactamases mediated resistance. Soon after 
introduction, the first report of plasmid coded β-
lactamases capable of hydrolyzing extended 
spectrum cephalosporin was published in 
Germany (1983)1. Hence, these new β-lactamases 
were coined as extended spectrum β-lactamases 
(ESBLs). 
ESBLs are β-lactamases capable of conferring 
bacterial resistance to penicillins, first, second, 
and third-generation cephalosporins, and 
aztreonam (but not cephamycins or 
carbapenems) but are inhibited by β-lactamase 
inhibitors such as clavulanic acid. Plasmids 
responsible for ESBLs production frequently 
carry genes encoding resistanceto other drug 
classes also (e.g. aminoglycosides). Therefore, 
antibiotic options for ESBLs producing 
organisms are limited. Carbapenems are the 
treatment of choice for serious infections due to 
ESBLs producing organisms, yet carbapenem-
resistant isolates have recently been reported. 
ESBLs represent an impressive example of 
ability of gram-negative bacteria to develop new 
antibiotic resistance mechanisms in face of the 
introduction of new antimicrobial agents2. 
Therefore infections due to ESBL isolates 
continue to pose a challenge to infection 
management worldwide3. 
Patients at high risk for developing infection 
with ESBLs producing organisms are often 
seriously ill with prolonged hospital stays and 
in whom invasive medical devices are present 
(urinary catheters, endo-tracheal tubes, central 
venous lines etc.) for a long duration. Heavy 
antibiotic use is also a risk factor for acquisition 
of ESBLs producing organisms4. 
Detecting presence of ESBLs producing 
pathogens influences choice of appropriate 
antibiotic therapy. In addition, detection can 
also aid in infection-control measures by helping 
to guide patient isolation procedures5.Hence, 
there is a need for better detection of ESBLs in 
clinical laboratory.  
Keeping above facts in note, this study was 
undertaken to find the prevalence of ESBLs 
producer Escherichia Coli isolated from different 
samples received from different wards of G. K. 
General Hospital, Bhuj (Gujarat). Studyalso 
includes comparison of antibiotic susceptibility 
pattern of ESBLs producers with non–ESBLs 
producers. 
 
SUBJECTS AND METHODS 
The study comprises of total 100 clinical isolates 
of  E.Coli  from different samples received at 
diagnostic Microbiology laboratory of G.K. 
General Hospital and Gujarat Adani Institute of 
Medical Sciences, Bhuj (Gujarat), India, during 
the period from June to November 
2011.Theidentification of isolated organism was 
performed by conventional biochemical tests 
using standard microbiological techniques6.  
Antibiotic Sensitivity Testing: The 
susceptibility of ESBLs producing bacteria to 
amikacin, piperacillin-tazobactam, amoxicillin 
/clavulanic acid, gentamicin, ciprofloxacin and 
imepenemwere determined by Kirby-Bauer disc 
diffusion method according to the Clinical 
Laboratory Standards Institute (CLSI) 
Guidelines7. 
ESBL screening test: According to CLSI 
guidelines, isolates showing inhibition zone size 
of ≤ 22 mm with Ceftazidime (30 μg), ≤ 25 mm 
with Ceftriaxone (30 μg), and ≤ 27 mm with 
Cefotaxime(30  μg) were identified as ESBLs 
producers and shortlisted for confirmation of 
ESBLs production. 
Combination Disc Method:The combination-
disc test using both cefotaxime and ceftazidime, 
alone and in combination with clavulanic acid, 
was performed for the detection of ESBLs 
according to the CLSI guidelines7.  
In this test, an overnight culture suspension of 
the test isolate which was adjusted to 0.5 
McFarland’s standard was inoculated by using 
sterile cotton swab on the surface of a Mueller 
Hinton Agar plate. The Cefotaxime (30μg) and 
cefotaxime-clavulanic acid (30μg / 10μg) discs 
were placed 20mm apart on the agar. Similarly, 
the ceftazidime (30 μg) and ceftazidime-
clavulanic acid (30μg/ 10μg) discs were placed 
20 mm apart. After incubating overnightat37°C, 
≥ 5-mm increase in the zone diameter for either 
antimicrobial agent which were tested in 
combination with clavulanic acid versus its zone 
when tested alone, was interpreted as positive 
for ESBLs production7. 
MIC Reduction Test:The isolates positive with 
combination disc test were further confirmed for  
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ESBLs production by this test. Minimum 
inhibitory concentration of the isolates was 
determined by broth dilution method. 
Concentrations of antibiotics tested: 
Ceftazidime (0.25 to 128 μg/ml), Ceftazidime 
plus clavulanic acid (0.25/4 to 128/4 μg/ml), 
Cefotaxime (0.25 to 64 μg/ml), and Cefotaxime 
plus clavulanic acid (0.25/4 to 64/4 μg/ml), 
Phenotypic confirmation is considered as a >3-
two fold serial dilution decrease in MIC of either 
cephalosporin in the presence of clavulanic acid 
compared to its MIC when tested alone.  
Quality Control: Escherichia Coli ATCC 25922 
was used for the quality control of the ESBLs 
testing methods and the Kirby-Bauer disc 
diffusion method. 
Statistical Analysis: Chi-square (χ2) test was 
used to check the association in between 
variation. Where the cell frequency was less 
than five, Yates correction was applied to see the 
significance of difference between the resistance 
levels of various drugs in ESBLs producer 
strains and non-ESBLs producer strains using 
SPSS version15. P ≤ 0.01 was considered 
significant. 
 
RESULTS 
A total of 100 isolates of E .Coli were recovered 
from different clinical samples from different 
wards of tertiary care G K General Hospital. 
Majority of isolates were obtained from 
medicine and surgery wards. Least number of 
isolates obtained from obstetrics and gynecology 
wards may be due to less frequency of samples 
being received (Table 1). 
 
Table 1: Distribution of ESBL positive isolates 
in different clinical wards 
Organism  
(E. Coli) 
Isolates  
tested 
ESBLs  
Producers (%) 
Medicine  33 22  (66.67) 
Surgery  28 19  (67.86) 
PICU  15 8  (53.33) 
Ortho. & ENT  7 2  (28.57) 
Obs. & Gyn.  4 1  (25.00) 
Paediatrics  13 6  (46.15) 
Total  100 58  (58.00) 
 
Highest isolates were obtained from urine 
sample. Lowest number of isolates were 
obtained from pus and drain sample (Table 2). 
Out of 100 isolated strains of E.Coli, 69 strains 
were short listed as potential ESBLs producers 
in screening test. Of these 69 ESBL screening 
positive strains, 58 strains were found to be 
ESBLs producers by combination disc test. This 
was further confirmed by MIC reduction test 
using broth dilution method.Results of 
combination disc and MIC reduction test were 
in concordance (Table 3). 
 
Table 2: Distribution of ESBL positive isolates 
in different clinical samples 
Organism  
(E.Coli) 
Isolates  
tested 
ESBLs  
Producers (%) 
Blood  21 12  (57.14) 
Urine  35 27  (77.14) 
Sputum  14 6  (42.86) 
Wound  21 11  (52.38) 
Pus / Drain  4 1  (25.00) 
Other Body Fluids  5 1  (20.00) 
Total  100 58  (58.00) 
 
A significant proportion of the ESBLs producing 
strains were found to be resistant to 
antimicrobial agents including ampicillin 
(87.93%), piperacillin (72.41%), ciprofloxacin 
(91.37%) and gentamicin (62.06%). 
 
Table 3:  Result of screening and confirmatory 
test for ESBLproduction 
Total E.Coli isolates 100 
Isolates positive in screening test  69 
Isolates positive in combination disc test  58 
Isolates positive in MIC reduction test  58 
 
The highest rate of resistance in ESBLs negative 
isolates was seen against ciprofloxacin (66.66%) 
which was significantly (p < 0.01) lower than 
ESBLs producing isolates. This was followed by 
resistance to ampicillin (42.85%). ESBLs 
producer and ESBLs non producer isolates 
were100% sensitive to piperacillin + tazobactam 
and imipenem. ESBLs producing isolates were 
resistant to more antimicrobial agents than non-
ESBLs producing isolates. Multidrug resistance 
was seen more in ESBLs positive isolates than 
non-ESBLs isolates (Table 4). 
Thus, 58% (58/100) were found to be ESBL 
producers. Distribution of this ESBL positive 
isolates was highest among urine samples 
accounting for 77.14% of all isolates recovered 
(Table 2).The highest ESBL positive isolates 
were found in surgery and medicine wards 
67.86% and 66.67% respectively (Table 1).  
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Table 4: Antibiotic susceptibility pattern of ESBL & Non-ESBLproducers 
Antibiotic  Resistant ESBL non 
producer (n=42) 
Resistant ESBL 
producer (n=58) 
χ2 p-value  df 
Ciprofloxacin  28 (66.66%)  53 (91.37%)  9.67  0.001  1 
Gentamicin  10 (23.80%)  36 (62.06%)  14.35  <0.001  1 
Amikacin 7  (16.66%)  13  (22.41%)  0.05  0.4782  1 
Ampicillin  18 (42.85%)  51 (87.93%)  23.14  <0.001  1 
Piperacillin 8  (19.04%)  42  (72.41%)  27.75  <0.001  1 
Piperacillin + tazobactam  0  0  ---  ---  --- 
Chloramphenicol 3(7.14%)  19  (32.75%)  7.88  0.005  1 
Imipenem 0  0  ---  ---  --- 
 
DISCUSSION 
This study demonstrated the presence of ESBL 
mediated resistance in E. Coli isolated at our 
institute. The prevalence was 58%. The overall 
prevalence of ESBL producers was found to 
vary greatly in different geographical areas and 
in different institutes. Previous studies from 
India have reported ESBL production varying 
from 28% to 84% 8.There is considerable 
geographical difference in ESBLs in European 
countries. Within countries, hospital-to-hospital 
marked variability occurs9. 
A study from North India on uropathogens such 
as  Klebsiella pneumoniae,  Escherichia Coli, 
Enterobacter, Proteus and Citrobacter spp showed 
that 26.6% of the isolates were ESBL producers. 
A study from Nagpur showed that 48.3% of 
their cefotaxime resistant Gram negative bacilli 
were ESBL producers10. A report from 
Coimbatore (India) showed that ESBL 
production was 41% in E. Coli and 40% in K. 
pneumonia11. In a similar study by Mathur et al, 
6 2 %  o f  t h e  E .  C o l i  a n d  7 3 %  o f  t h e  K .  
pneumoniae isolates were reported to be ESBL 
producers12. In the present study, we also 
observed that 81% of the E. Coli and that 74% of 
the K. pneumoniae isolates were ESBL 
producers. Although, K. pneumonia were more 
often reported as ESBL producers in other 
studies, we observed that, ESBL production was 
more common among the E. Coli isolates as 
compared to the K. pneumoniae isolates11,12.  
The high rate of resistance noted among the 
isolates in the present study is of serious 
concern. 62% of isolates were ESBL producing. 
In this study, ESBL producing isolates were 
significantly more resistant to ampicillin, 
ciprofloxacin, piperacillin and gentamicin as 
compared to non-ESBL producing Gram-
negative isolates. We studied the occurrence of 
multi-drug resistance among the E. Coli and K. 
pneumonia isolates and found that co-resistance 
to ampicillin, gentamicin and ciprofloxacin was 
very common. Mechanisms of co-resistanceare 
not clear, but one possible mechanism is the co-
transmission of ESBL and resistance to other 
antimicrobials within the same conjugative 
plasmids13. Almost all the ESBL-positive isolates 
were found to be resistant to Ampicillin and 
sensitive to Imipenem, which again advocates 
the usage of carbapenem antibiotics as the 
therapeutic alternative to β-lactam antibiotics as 
indicated in our study, we observed that a 
majority of the isolates were susceptible to 
imipenem and piperacillin-tazobactam. 
Similarly, in a study from Coimbatore, all the 
members of Enterobacteriaceae were susceptible 
to piperacillin-tazobactam and imipenem.14  Of 
all the available antimicrobial agents, 
carbapenems are the most active and reliable 
treatment options for infections which are 
caused by the ESBL producing isolates.15 
However, the over use of carbapenems may lead 
to resistance in Gram-negative organisms. The 
regular detection of ESBLs by conventional 
methods should be carried out in every lab 
where molecular methods cannot be performed, 
as genotyping is not more in formative for the 
treatment. 
In conclusion, the prevalence of ESBL producers 
at our institute was 58% in accordance to the 
prevalence reported from other hospitals in 
India as well as across the globe. Multi drug 
resistance was significantly (p <0.01) higher in 
ESBL positive isolates than non-ESBL isolates. 
Hence, the ESBL-producing organisms are 
abreed of multidrug-resistant pathogens that are 
increasing rapidly and becoming a major 
problem in the area of infectious diseases. It is 
essential to report ESBL production along with 
the routine sensitivity reporting, which will help 
the clinicians in prescribing proper antibiotics. 
Phenotypic confirmatory test using combination 
disc is simple and cost effective for the detection 
of ESBL production as it has shown 100%  
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concordance with MIC reduction test. 
Piperacillin-tazobactam and imipenem are the 
most active and reliable agents for the treatment 
of infections which are caused by ESBL 
producing organism. Apart from reliable 
methods for laboratory reporting of ESBLs, the 
control measures include judicious use of 
antibiotics, strict hand-hygiene protocols, and 
implementation of appropriate infection-control 
measures in the hospital, especially while 
treating high risk patients. 
 
CONCLUSIONS & RECOMMENDATIONS 
Multidrug resistance was significantly higher in 
ESBL positive isolates. Knowledge of the 
prevalence of ESBLs and resistance pattern of 
bacterial isolates in a geographical area is of 
utmost importance. It is essential to report ESBL 
production along with the routine sensitivity 
reporting, which will help the clinicians in 
prescribing the proper antibiotics. 
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